The group's principal activity is to develop artificial heart technologies. The group is focused on two technologies, novacor lvas and the heartsaver ventricular assist device (heartsaver). Novacor technology is currently in commercial production and the heartsaver technology is currently under development. This technology is being developed from licensed artificial heart and related technologies developed by the cardiovascular devices division (cvd) of the ottawa heart institute research corporation. The operations of the group are carried out in oakland, California, the United States, ottawa, ontario and Canada.
